ArticleDiscover oncology2025
Intratumor heterogeneity related signature for clinical outcome and immunotherapy advantages in lung adenocarcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Overexpression of GM3 and Ganglioside Pattern Remodeling in Lung Adenocarcinoma Brain Metastases Identified by Ion Mobility Mass Spectrometry.International journal of molecular sciences · 2025Article
- PIN1 serves as a prognostic and therapeutic biomarker in lung adenocarcinoma.Functional & integrative genomics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunotherapy benefits shows discrepancy in different lung adenocarcinoma (LUAD) patients because of the intratumor heterogeneity (ITH). ITH favors tumor evolution and correlated with drug resistance. The genes mediating ITH in LUAD and their role in predicting prognosis and therapy benefits is unclear.
methodsAn ITH-related signature (IRS) was built by ten methods-based integrative machine learning programs using TCGA, GSE68571, GSE42127, GSE30129, GSE50081, GSE72094, GSE37745, GSE68467, and GSE31210 dataset. To assess the relationship between IRS and the tumor immune microenvironment, numerous prediction scores were employed.
resultsThe optimal predictive signature for LUAD cases was the IRS developed using Lasso + stepCox(both) method, which had the highest average C-index of 0.80. It performed consistently and effectively in predicting the clinical outcomes of LUAD patients. Additionally, compared to the clinical stage and numerous other existing prediction models, a higher C-index was demonstrated in IRS. LUAD patients with low IRS score had a higher level of immuno-activated cells, higher TMB score, lower ITH score, higher PD1&CTLA4 immunophenoscore, and tumor escape score in LUAD. The gene set score for angiogenesis, coagulation, hypoxia, and NOTCH signaling were increased in LUAD with high IRS score.
conclusionOverall, the study developed a unique IRS for LUAD that may serve as a predictor of the clinical outcome and immunotherapy advantages for individuals with LAUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.